A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)Cristina Mussini, Franco Maggiolo, Silvia Nozza et al.|PLoS ONE|2019Cited by 16
Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based RegimensSilvia Baroncelli, Marco Floridia, Maria Franca Pirillo et al.|AIDS Research and Human Retroviruses|2014Cited by 10